In the field of pharmaceuticals, Wockhardt is gaining a reputation in several parts of the world as a name to trust. Over the past 45 years, starting from its roots in India, Wockhardt has grown to a billion dollar worldwide organization, today spanning 14 countries in 5 continents. More than 10,000 employees working in offices, 20 manufacturing facilities, 5 research centers, and hospitals are completely dedicated to building an important trust in our products.
At Wockhardt, we draw our strength from the formidable foundation of trust built over the years through delivering quality products by continuously investing into R&D and modern manufacturing technologies, as well as contemporary processes. This enables us to deliver worldclass quality products. At Wockhardt, we don’t merely formulate medicines, we formulate trust.
We believe that quality medicines begin with strong science and that the quality of our products is directly related to the integrity of our people. Over 525 Quality Control and Quality Assurance scientists guarantee that Wockhardt’s products and its 20 worldwide manufacturing facilities and 5 research centers meet the strict quality standards set by the FDA. Our world-class global R&D facilities are at the heart of Wockhardt’s pledge and commitment to deliver high quality medicines at affordable prices and all are fully compliant with cGMP quality standards.
Wockhardt USA LLC is leading the way in developing the most complete, high-quality line of generic oral solids, liquids, topicals, and injectables available in the United States. Wockhardt USA now represents more than 20% of Wockhardt Ltd’s global business, providing more than 210 NDCs spanning more than 75 different product families. We have been producing and distributing quality products in the United States for more than 14 years and have received over 110 ANDA approvals to date.
Wockhardt USA has demonstrated revenue growth of 70% for fiscal year 2010 in the world’s largest and most competitive pharmaceutical market and is geared to derive maximum value from it. With over 110 products marketed in the United States, Wockhardt USA has 13 products ranked in the No. 1 position and another 15 products in the No. 2 position in their respective therapeutic groups in the United States (Wolters Kluwer—September 2010).
Wockhardt USA’s recent 2011 approvals include: Donepezil tablets, Levofloxacin tablets, and Venlafaxine ER capsules.
Other key products in the Wockhardt USA product line include: Azithromycin tablets, Divaloproex ER tablets, Enalapril tablets, Metoprolol Succinate ER tablets, Nicardipine Injection, Ropinirole HCl tablets, Ceftriaxone Injection, Tamsulosin capsules, Hydrocodone and Homatropine syrup, Megestrol Acetate Oral Suspension, Nystatin Oral Suspension, and Phenytoin Oral Suspension. PT
For more information, please visit www.wockhardtusa.com.